VIVEVE MEDICAL INC - VIVE STOCK NEWS

Viveve Medical, Inc. (NASDAQ:VIVE) has completed enrollment in its pivotal PURSUIT clinical trial designed to evaluate the efficacy and safety of its treatment for stress urinary incontinence (SUI)FDA approval for this new indication, with topline results expected by the end of 2022. The company seeks to offer a safe, effective treatment for the millions of women affected by SUI.

Viveve Medical (NASDAQ: VIVE) reported Q3 2021 revenue of $1.6 million, an increase from $1.5 million in Q3 2020. The growth is attributed to sales of 16 Viveve Systems and around 2,300 consumable treatment tips. The company's pivotal SUI PURSUIT trial is nearing full patient randomization, expected to conclude in Q4. However, total operating expenses rose to $5.6 million, leading to a net loss of $7.0 million or ($0.67) per share. Cash reserves decreased to $22.7 million as of September 30, 2021.

Viveve Medical, Inc. (NASDAQ:VIVE) announced its third quarter 2021 financial results report scheduled for November 11, 2021, post-market close. A conference call will follow at 5:00 PM ET, accessible via phone or live webcast. The Company will file its 10-Q documents on November 12, 2021. Viveve focuses on women's health technologies, notably using Cryogen-cooled Monopolar Radiofrequency technology. The company is advancing its clinical program for stress urinary incontinence with FDA-approved protocol changes aimed at enhancing study efficacy.

Viveve Medical, Inc. (NASDAQ:VIVE) announced the issuance of U.S. Patent No. 11,154,349 by the USPTO, enhancing its intellectual property portfolio related to its dual-energy technology. CEO Scott Durbin highlighted the company's commitment to intellectual property protection, enabling its clinical development and commercialization strategies. Viveve is advancing clinical trials in stress urinary incontinence (SUI), with recent FDA-approved protocol changes aimed at improving study efficacy. Positive outcomes may support new SUI indications in the U.S.

Viveve Medical announced the issuance of Patent No. 2016324168 by the Australian Patent Office, covering its innovative treatment method for stress urinary incontinence (SUI) in women. This patent strengthens Viveve's intellectual property portfolio, coinciding with enrollment in the pivotal U.S. PURSUIT clinical trial aimed at addressing SUI. The company's dual-energy technology has shown promise in improving connective tissue function non-invasively, and positive trial results could lead to new U.S. indications for SUI treatment.

Viveve Medical (NASDAQ:VIVE) announced that CEO Scott Durbin will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation is scheduled for September 13, 2021, at 7:00 AM ET and will be accessible via webcast on the company's website. Viveve focuses on women’s intimate health, utilizing its patented Viveve® System for various medical treatments. The company is advancing its clinical program for Stress Urinary Incontinence (SUI) and aims to achieve a new indication in the U.S. if trial results are positive.

Viveve Medical reported Q2 2021 total revenue of $1.7 million, a substantial increase from $0.7 million in Q2 2020. The company sold approximately 3,500 consumable treatment tips, marking a 42% quarter-over-quarter unit increase. The enrollment for the pivotal SUI PURSUIT trial is on track for completion by early Q4 2021. A new Category III CPT code was established, offering potential long-term reimbursement pathways. However, total operating expenses rose to $5.1 million, resulting in a net loss of $5.2 million for the quarter.

Viveve Medical (NASDAQ:VIVE) will announce its Q2 2021 financial results on August 12, 2021, after U.S. markets close. A conference call is scheduled for 5:00 PM ET, accessible via phone or webcast. The company is advancing its clinical development for Stress Urinary Incontinence (SUI) with recent FDA-approved changes to the PURSUIT trial protocol, enhancing its chances of achieving primary efficacy endpoints. Viveve is committed to women's intimate health, offering a patented system for volumetric heating and neocollagenesis. Further details on the trial and financial performance will be provided during the call.

Viveve Medical (NASDAQ: VIVE) announced the issuance of Canadian Patent No. 3028905 for its dual-energy technology device, enhancing its intellectual property (IP) portfolio. This patent follows recent expansions, including a U.S. patent and two Asia Pacific patents. CEO Scott Durbin highlighted the importance of this patent in advancing their clinical and commercialization strategies. Viveve's patented system is designed to improve women's health, with FDA clearance for surgical procedures and international approvals for treating vaginal laxity and enhancing sexual function.